<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CE562D3D-45D5-45B3-99FF-A81611187A1C"><gtr:id>CE562D3D-45D5-45B3-99FF-A81611187A1C</gtr:id><gtr:name>Veterinary Services</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:department>Institute of Life Science Medical School</gtr:department><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CE562D3D-45D5-45B3-99FF-A81611187A1C"><gtr:id>CE562D3D-45D5-45B3-99FF-A81611187A1C</gtr:id><gtr:name>Veterinary Services</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/11661991-0F9E-40DB-A618-13463BEA156F"><gtr:id>11661991-0F9E-40DB-A618-13463BEA156F</gtr:id><gtr:firstName>Ceri</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2AFF11F2-42FE-4754-BBD9-36A89E3EF454"><gtr:id>2AFF11F2-42FE-4754-BBD9-36A89E3EF454</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Skerrett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B16FB976-E7F1-4BDA-BCDC-FB33FD795E76"><gtr:id>B16FB976-E7F1-4BDA-BCDC-FB33FD795E76</gtr:id><gtr:firstName>Sharon</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A33E8994-FD55-40AD-BF5D-31CD2B770EE2"><gtr:id>A33E8994-FD55-40AD-BF5D-31CD2B770EE2</gtr:id><gtr:firstName>Stefan</gtr:firstName><gtr:surname>Siebert</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7D6560DD-5C24-443C-9C64-BC770B160A0A"><gtr:id>7D6560DD-5C24-443C-9C64-BC770B160A0A</gtr:id><gtr:firstName>Ronan</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Lyons</gtr:surname><gtr:orcidId>0000-0001-5225-000X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0AEC3FA7-B22E-4B35-9C01-43B932962AB5"><gtr:id>0AEC3FA7-B22E-4B35-9C01-43B932962AB5</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Gravenor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/50BD60B5-6CBC-4300-9455-4B73D873DD84"><gtr:id>50BD60B5-6CBC-4300-9455-4B73D873DD84</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Ford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5D667CB2-D0C5-4912-A5AC-E71176D4427E"><gtr:id>5D667CB2-D0C5-4912-A5AC-E71176D4427E</gtr:id><gtr:firstName>Sinead</gtr:firstName><gtr:surname>Brophy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800583"><gtr:id>5C253D5B-6646-4164-9909-B318A81121B4</gtr:id><gtr:title>A Population-based Ankylosing Spondylitis [PAS] cohort</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800583</gtr:grantReference><gtr:abstractText>Studying long term conditions can be difficult as a result of the timescale involved and the difficulty in capturing associated non-medical costs such as disability or lack of earnings due to illness. A great deal of information is already regularly collected on all people using the NHS. However, this information is held in many different NHS systems, such as with the general practitioner, their specialist, the hospital and laboratories. By linking this information, people with specific conditions can be followed through the health system. In addition, these people can also contribute directly to the data collected by completing questionnaires about the effects of their disease, such as function or pain. This information can be fed back to their usual doctor, thereby contributing to their personal care, while also improving the quality and value of the data collected. In this study we intend to apply these strategies of linking data relating to people living in Wales with ankylosing spondylitis, the second most common inflammatory arthritis. This data will be collected and analysed in a secure and anonymised manner to help address important research questions about this condition. For example, this linked information will help us to better understand the variations in this lifelong condition; help to predict early in the disease which patients will develop the most disabling disease requiring more aggressive therapy; facilitate estimates of the true cost of this condition, thereby speeding up assessments of expensive new treatments as they become available; and help to better plan the pathway of these patients through the health system. This study will facilitate genetic and biological studies, as well as trials of new medications for ankylosing spondylitis, thereby further improving understanding of this condition and attracting high quality research to the NHS. The methods used here build on existing resources in the UK and can also be applied to many other conditions in the future.</gtr:abstractText><gtr:technicalSummary>Ankylosing spondylitis (AS) is the second most common form of inflammatory arthritis. However, the natural history of AS is poorly understood with considerable variability in presentation and progression. In particular, there is a paucity of research on the cost of AS which has resulted in delayed NICE approval of new effective therapies for AS. The cost-effectiveness issue is further limited by the current inability to identify patients at risk of developing aggressive disease (who would benefit most from early aggressive therapy) and inability to predict which patients will fail to respond to these therapies. Identifying and recruiting AS patients, in a prompt and cost-effective manner, for genetic validation studies and clinical trials of new therapies is becoming increasingly difficult in the current fragmented NHS system. This proposal is for a population based cohort of people with AS, utilising disease-specific data (rheumatology database, radiology imaging) and patient-centred data (quality of life, work limitations, disease activity, function) linked with existing electronic data from disparate clinical, laboratory and administrative systems held by HIRU (GP records, out-patient and in-patient data, laboratory, A&amp;amp;E, social services datasets etc). All patients with AS (diagnosed by a rheumatologist) living in Wales will be approached to participate in this cohort, resulting in a well characterised cohort with robust clinical data at its base. The unique link with existing datasets will allow the cohort to be followed both prospectively and retrospectively. Therefore the cohort can be used to provide data on the natural history of AS, give an objective estimate of the cost of AS at each stage of the disease, identify early risk factors for severe disease, help identify potential interventions to prevent surgery and disability, in addition to facilitating patient identification and recruitment for genetic studies and clinical trials of new interventions. This study builds on existing UK resources and enhances the NHS?s ability to attract research. The cohort can also contribute to registers and post-marketing surveillance of new therapies. The use of routine data will ensure that this study will not suffer from the ?cohort effect? as all patients nationally can be included in the linking of routine data, and the use of rheumatology and GP clinical records will ensure the cohort will not date with time as it will include all new patients every year. Therefore this cohort, which can act as a pilot for other conditions, builds on and enhances existing UK resources and infrastructure.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>203728</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Sciences Division</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases (NDORMS)</gtr:department><gtr:description>Genetics of AS study</gtr:description><gtr:id>AE580BFB-04F0-4956-A79A-B82C6BED20BB</gtr:id><gtr:impact>Still ongoing - will result in publications with authorship for our team.</gtr:impact><gtr:piContribution>Recruited participants from our cohort.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Information day for participants and patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BC96AD91-3227-410F-A93E-3C64DE70C027</gtr:id><gtr:impact>95 patients and carers attended information day with talks and Q&amp;amp;A session.

Increased interest and recruitment in study. Increased membership numbers in local patient groups. Increased knowledge about ankylosing spondylitis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7th Annual UK Day on Spondyloarthritis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BDCCCA8-CC73-4A01-B829-01F4BEFF422D</gtr:id><gtr:impact>70+ UK Healthcare professionals (doctors, physios and specialist nurses), researchers and patient advisory group representatives (from NASS) as part of a 2 day programme on advances in clinical and research aspects related to spondyloarthritis

Information relevant to clinical practice, including several aspects that will result in changes to clinical practice. Also has lead to discussions about further collaboration.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Welsh Assembly Government information session</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CC44F23-9F67-46E6-BC0F-E203205FB646</gtr:id><gtr:impact>Presentation to Welsh AMs, healthcare professionals, NHS policy makers, patients and patient groups at special session on Ankylosing Spondylitis

Information from cohort was used to emphasise burden and healthcare needs of patients with AS in Wales, which would be fed into teh chronic diseases management policies.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media releases</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2C125CA3-C3FF-444B-9C3B-F26526C413B3</gtr:id><gtr:impact>Regional media promotion for the study information day.

Increased interest and knowledge about the condition (Ankylosing spondylitis) and the research activities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scottish Parliament Cross Party Group on Musculoskeletal Disorders</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>396D30A1-0607-4F55-AE61-7B6ED90B9201</gtr:id><gtr:impact>Scottish Parliament Cross Party Group on Musculoskeletal disorders and arthritis - event on Ankylosing Spondylitis and cost of arthritis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participant newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ECBB6313-67D6-4BD6-A98C-9077999E17A6</gtr:id><gtr:impact>Newsletter with updates of research and other AS topics of interest

Increased retention of participants in study and dissemination of information about study beyond participants. Increased knowledge about ankylosing spondylitis.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CBC0F83D-19FE-4951-A4D4-A892D6322F92</gtr:id><gtr:impact>Presentations to regional and national rheumatologists at clinical meetings

Increased participation of clinicians in research in Ankylosing Spondylitis. Development of regional clinical ankylosing spondylitis interest groups.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>44234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer Inflammation-Competitive Research Programme (I-CRP)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:fundingRef>WS2306062</gtr:fundingRef><gtr:id>97B91746-C38D-41E3-80E0-CED9BC192027</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BSR Guidelines for Ankylosing Spondylitis</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2C43BDA4-3C67-4041-B363-B90ADF2B8DA0</gtr:id><gtr:impact>Review and update of British Society for Rheumatology (BSR) national guidelines for the management of ankylosing spondylitis.</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.rheumatology.org.uk/resources/guidelines/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Methodology for improving the validity of health economic data analysis using longitudinal routine data linked with patient completed data.
Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods.</gtr:description><gtr:id>930B8D7E-FDE2-428B-A8A9-F9C6E5BF10DF</gtr:id><gtr:impact>Presented as poster at the MRC Clinical Trials Methodology Conference in October 2011. 
Published doi: 10.1371/journal.pone.0126105 and doi: 10.1016/j.jval.2015.02.016.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Health economic analysis using linked routine data</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B637CCE-E4F1-4CF3-9881-6EAA3F53F3C6"><gtr:id>4B637CCE-E4F1-4CF3-9881-6EAA3F53F3C6</gtr:id><gtr:title>Fatigue in ankylosing spondylitis: treatment should focus on pain management.</gtr:title><gtr:parentPublicationTitle>Seminars in arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b8463986117a8152e0b5190d0344633"><gtr:id>3b8463986117a8152e0b5190d0344633</gtr:id><gtr:otherNames>Brophy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-0172</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/14A7155A-F360-45A8-8051-D8B2C7683F3D"><gtr:id>14A7155A-F360-45A8-8051-D8B2C7683F3D</gtr:id><gtr:title>The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd6c16530494114995f03eac7362532"><gtr:id>3fd6c16530494114995f03eac7362532</gtr:id><gtr:otherNames>Cooksey R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8BDEE77-6976-4D2D-B8BD-CC7A3D3AEFD0"><gtr:id>D8BDEE77-6976-4D2D-B8BD-CC7A3D3AEFD0</gtr:id><gtr:title>Severe flare as a predictor of poor outcome in ankylosing spondylitis: a cohort study using questionnaire and routine data linkage.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd6c16530494114995f03eac7362532"><gtr:id>3fd6c16530494114995f03eac7362532</gtr:id><gtr:otherNames>Cooksey R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/20AFD1B7-B75C-4AC3-A71B-F7AA6C7C4AA6"><gtr:id>20AFD1B7-B75C-4AC3-A71B-F7AA6C7C4AA6</gtr:id><gtr:title>Protocol for a population-based ankylosing spondylitis (PAS) cohort in Wales.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b05d2ed48391a88e60d5ac7f88222a6"><gtr:id>6b05d2ed48391a88e60d5ac7f88222a6</gtr:id><gtr:otherNames>Atkinson MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C47CF36D-C5AB-447D-BF95-42F145FE0520"><gtr:id>C47CF36D-C5AB-447D-BF95-42F145FE0520</gtr:id><gtr:title>HERALD (health economics using routine anonymised linked data).</gtr:title><gtr:parentPublicationTitle>BMC medical informatics and decision making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90e5afb78964d0f6289c1d5564c46a57"><gtr:id>90e5afb78964d0f6289c1d5564c46a57</gtr:id><gtr:otherNames>Husain MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1472-6947</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC1C3BC4-4E2A-4110-95E3-BD68ADC18F8C"><gtr:id>EC1C3BC4-4E2A-4110-95E3-BD68ADC18F8C</gtr:id><gtr:title>Frequency and characteristics of disease flares in ankylosing spondylitis.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd6c16530494114995f03eac7362532"><gtr:id>3fd6c16530494114995f03eac7362532</gtr:id><gtr:otherNames>Cooksey R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/439308DA-2AB9-4689-972B-1B7505542464"><gtr:id>439308DA-2AB9-4689-972B-1B7505542464</gtr:id><gtr:title>The effect of physical activity and motivation on function in ankylosing spondylitis: a cohort study.</gtr:title><gtr:parentPublicationTitle>Seminars in arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b8463986117a8152e0b5190d0344633"><gtr:id>3b8463986117a8152e0b5190d0344633</gtr:id><gtr:otherNames>Brophy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-0172</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DFE8924-7A4E-4FF2-96FC-007A35A522EE"><gtr:id>8DFE8924-7A4E-4FF2-96FC-007A35A522EE</gtr:id><gtr:title>The information needs of people living with ankylosing spondylitis: a questionnaire survey.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd6c16530494114995f03eac7362532"><gtr:id>3fd6c16530494114995f03eac7362532</gtr:id><gtr:otherNames>Cooksey R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/334E62FC-C408-4A6E-A9EA-3D2EFEA75461"><gtr:id>334E62FC-C408-4A6E-A9EA-3D2EFEA75461</gtr:id><gtr:title>Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ec9e95b51c56f8430337abd3acbabe8"><gtr:id>9ec9e95b51c56f8430337abd3acbabe8</gtr:id><gtr:otherNames>Wailoo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB1F5FE3-A1CC-48C9-AE26-907D8AB76D05"><gtr:id>AB1F5FE3-A1CC-48C9-AE26-907D8AB76D05</gtr:id><gtr:title>Patient perspectives of managing fatigue in Ankylosing Spondylitis, and views on potential interventions: a qualitative study.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e5ff382bd84d9eb14346b298e2c2680"><gtr:id>3e5ff382bd84d9eb14346b298e2c2680</gtr:id><gtr:otherNames>Davies H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBACED26-2FB8-4D28-841E-A45C708E895E"><gtr:id>DBACED26-2FB8-4D28-841E-A45C708E895E</gtr:id><gtr:title>No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data.</gtr:title><gtr:parentPublicationTitle>Seminars in arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b8463986117a8152e0b5190d0344633"><gtr:id>3b8463986117a8152e0b5190d0344633</gtr:id><gtr:otherNames>Brophy S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0049-0172</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800583</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>